口服二价伤寒沙门氏菌-宋内志贺氏菌疫苗或被致病性宋内志贺氏菌感染后人类外周血中特异性分泌免疫球蛋白A的细胞
Specific immunoglobulin A-secreting cells in peripheral blood of humans following oral immunization with a bivalent Salmonella typhi-Shigella sonnei vaccine or infection by pathogenic S. sonnei.
作者信息
Van de Verg L, Herrington D A, Murphy J R, Wasserman S S, Formal S B, Levine M M
机构信息
Department of Medicine, University of Maryland, School of Medicine, Baltimore 21201.
出版信息
Infect Immun. 1990 Jun;58(6):2002-4. doi: 10.1128/iai.58.6.2002-2004.1990.
Abstract
The ability of bivalent Salmonella typhi-Shigella sonnei vaccine strain 5076-1C to stimulate an intestinal immunoglobulin A response in humans was evaluated by detecting gut-derived, trafficking antibody-secreting cells (ASC) in peripheral blood. Following vaccination, an immunoglobulin A-ASC response to O antigens of S. typhi and S. sonnei was observed in 10 of 13 and 13 of 13 vaccine recipients, respectively. Experimental challenge with pathogenic S. sonnei stimulated an ASC response to the S. sonnei O antigen in all subjects who developed clinical illness. The magnitude of the ASC response to challenge was significantly greater than that resulting from vaccination. Furthermore, compared with the response of the unimmunized controls, individuals previously immunized with 5076-1C demonstrated a significantly greater ASC response following challenge with S. sonnei.
摘要
通过检测外周血中来源于肠道的、迁移性抗体分泌细胞（ASC），评估双价伤寒沙门氏菌-宋内氏志贺氏菌疫苗株5076-1C刺激人体肠道免疫球蛋白A反应的能力。接种疫苗后，分别在13名疫苗接种者中的10名和13名中观察到对伤寒沙门氏菌和宋内氏志贺氏菌O抗原的免疫球蛋白A-ASC反应。用致病性宋内氏志贺氏菌进行实验性攻击，在所有出现临床疾病的受试者中均刺激了对宋内氏志贺氏菌O抗原的ASC反应。攻击后ASC反应的幅度明显大于接种疫苗所产生的反应。此外，与未免疫对照组的反应相比，先前用5076-1C免疫的个体在受到宋内氏志贺氏菌攻击后表现出明显更强的ASC反应。
相似文献
1
Specific immunoglobulin A-secreting cells in peripheral blood of humans following oral immunization with a bivalent Salmonella typhi-Shigella sonnei vaccine or infection by pathogenic S. sonnei.
Infect Immun. 1990 Jun;58(6):2002-4. doi: 10.1128/iai.58.6.2002-2004.1990.
2
Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine.
J Infect Dis. 1987 Jun;155(6):1260-5. doi: 10.1093/infdis/155.6.1260.
3
Studies in volunteers to evaluate candidate Shigella vaccines: further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease.
Vaccine. 1990 Aug;8(4):353-7. doi: 10.1016/0264-410x(90)90094-3.
4
Safety and antigenicity of typhoid-Shigella sonnei vaccine (strain 5076-1C).
J Infect Dis. 1984 Feb;149(2):133-6. doi: 10.1093/infdis/149.2.133.
5
Stable expression of Shigella sonnei form I O-polysaccharide genes recombineered into the chromosome of live Salmonella oral vaccine vector Ty21a.
Int J Med Microbiol. 2013 Apr;303(3):105-13. doi: 10.1016/j.ijmm.2013.01.001. Epub 2013 Mar 7.
6
Quantitative analysis of IgG class and subclass and IgA serum response to Shigella sonnei and Shigella flexneri 2a polysaccharides following vaccination with Shigella conjugate vaccines.
Vaccine. 1999 Aug 6;17(23-24):3109-15. doi: 10.1016/s0264-410x(99)00136-x.
7
Development of a Live Attenuated Bivalent Oral Vaccine Against Shigella sonnei Shigellosis and Typhoid Fever.
J Infect Dis. 2017 Jan 15;215(2):259-268. doi: 10.1093/infdis/jiw528.
8
Detection of antibodies to Shigella lipopolysaccharide in urine after natural Shigella infection or vaccination.
Clin Diagn Lab Immunol. 1996 Jul;3(4):451-5. doi: 10.1128/cdli.3.4.451-455.1996.
9
Immune Response Characterization after Controlled Infection with Lyophilized Shigella sonnei 53G.
mSphere. 2020 Sep 23;5(5):e00988-19. doi: 10.1128/mSphere.00988-19.
10
Intestinal immunoglobulin A responses in rabbits to a Salmonella typhi strain harboring a Shigella sonnei plasmid.
Infect Immun. 1982 Jul;37(1):387-9. doi: 10.1128/iai.37.1.387-389.1982.
引用本文的文献
1
Safety, Tolerability, and Immunogenicity of the Invaplex Vaccine Co-Administered with the dmLT Adjuvant in Dutch and Zambian Adults: Study Protocol for a Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase Ia/b Clinical Trial.
Vaccines (Basel). 2025 Jan 8;13(1):48. doi: 10.3390/vaccines13010048.
2
A rhesus macaque intragastric challenge model for evaluating the safety, immunogenicity, and efficacy of live-attenuated 1 vaccine candidates.
Front Microbiol. 2024 Sep 6;15:1454338. doi: 10.3389/fmicb.2024.1454338. eCollection 2024.
3
Toward a Vaccine: Opportunities and Challenges to Fight an Antimicrobial-Resistant Pathogen.
Int J Mol Sci. 2023 Feb 28;24(5):4649. doi: 10.3390/ijms24054649.
4
The Vaccines Pipeline.
Vaccines (Basel). 2022 Aug 24;10(9):1376. doi: 10.3390/vaccines10091376.
5
Consensus Report on Shigella Controlled Human Infection Model: Immunological Assays.
Clin Infect Dis. 2019 Dec 9;69(Suppl 8):S596-S601. doi: 10.1093/cid/ciz909.
6
Evaluation of an intragastric challenge model for Shigella dysenteriae 1 in rhesus monkeys (Macaca mulatta) for the pre-clinical assessment of Shigella vaccine formulations.
APMIS. 2014 Jun;122(6):463-75. doi: 10.1111/apm.12168. Epub 2013 Sep 13.
7
Establishment of a Shigella sonnei human challenge model in Thailand.
Vaccine. 2012 Nov 19;30(49):7040-5. doi: 10.1016/j.vaccine.2012.09.061. Epub 2012 Oct 12.
8
The Shigella human challenge model.
Epidemiol Infect. 2013 Feb;141(2):223-32. doi: 10.1017/S0950268812001677. Epub 2012 Aug 21.
9
Antigen-specific IgA B memory cell responses to Shigella antigens elicited in volunteers immunized with live attenuated Shigella flexneri 2a oral vaccine candidates.
Clin Immunol. 2011 May;139(2):185-92. doi: 10.1016/j.clim.2011.02.003. Epub 2011 Mar 8.
10
Secretory IgA: arresting microbial pathogens at epithelial borders.
Immunol Invest. 2010;39(4-5):383-406. doi: 10.3109/08820131003622635.
本文引用的文献
1
Evaluation in humans of attenuated Vibrio cholerae El Tor Ogawa strain Texas Star-SR as a live oral vaccine.
Infect Immun. 1984 Feb;43(2):515-22. doi: 10.1128/iai.43.2.515-522.1984.
2
New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development.
Microbiol Rev. 1983 Dec;47(4):510-50. doi: 10.1128/mr.47.4.510-550.1983.
3
A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells.
J Immunol Methods. 1983 Dec 16;65(1-2):109-21. doi: 10.1016/0022-1759(83)90308-3.
4
A solid-phase immunoenzymatic technique for the enumeration of specific antibody-secreting cells.
J Immunol Methods. 1983 Feb 25;57(1-3):301-9. doi: 10.1016/0022-1759(83)90091-1.
5
Construction of a potential bivalent vaccine strain: introduction of Shigella sonnei form I antigen genes into the galE Salmonella typhi Ty21a typhoid vaccine strain.
Infect Immun. 1981 Dec;34(3):746-50. doi: 10.1128/iai.34.3.746-750.1981.
6
The response of man to virulent Shigella flexneri 2a.
J Infect Dis. 1969 Mar;119(3):296-9. doi: 10.1093/infdis/119.3.296.
7
Shigellosis in custodial institutions. II. Clinical, immunologic and bacteriologic response of institutionalized children to oral attenuated shigella vaccines.
Am J Epidemiol. 1972 Jul;96(1):40-9. doi: 10.1093/oxfordjournals.aje.a121431.
8
Immunity in shigellosis. II. Protection induced by oral live vaccine or primary infection.
J Infect Dis. 1972 Jan;125(1):12-6. doi: 10.1093/infdis/125.1.12.
9
Specific immunoglobulin-secreting human blood cells after peroral vaccination against Salmonella typhi.
J Infect Dis. 1986 Jun;153(6):1126-31. doi: 10.1093/infdis/153.6.1126.
10
B subunit-whole cell and whole cell-only oral vaccines against cholera: studies on reactogenicity and immunogenicity.
J Infect Dis. 1987 Jan;155(1):79-85. doi: 10.1093/infdis/155.1.79.
Zotero 插件